Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature
Medical Oncology, 10/23/2009
|
Karaca H et al. – The authors report a case of paraneoplastic hypercalcemia, resistant to conventional treatment but recovers by sunitinib treatment as the ... ndash;up period, in this case, serum calcium level was still in normal ranges. Besides sunitinib is effective in symptom control, it is also helpful in management of paraneoplastic hypercalcemia, a life–threatening entity.
[more...]
|
Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol
BMC Nephrology, 09/25/2009
|
hypercalcemia and hyperphosphatemia are associated with increased cardiovascular mortality in patients with chronic kidney disease. If there is any difference in the ability of these two vitamin D analogs to decrease the secondary hyperparathyroidism without causing hypercalcemia and
[more...]
|
Characterization and management of hypercalcemia following transplantation for osteopetrosis
Bone Marrow Transplantation, 10/08/2009
|
Martinez C et al. – Hypercalcemia is common in patients with OP within the first 4 weeks after HCT, and more likely in older patients. Isotonic saline, furosemide and s.c. calcitonin were well&ndash
[more...]
|
A Novel Loss-of-Function Mutation, Gln459Arg, of the Calcium-Sensing Receptor Gene Associated with Apparent Autosomal Recessive Inheritance of Familial Hypocalciuric Hypercalcemia
Journal of Clinical Endocrinology and Metabolism, 10/14/2009
|
Lietman SA et al. – The authors identified a novel loss–of–function Q459R mutation in the CASR gene that exhibits mildly ... importance of genetic testing in FHH to distinguish between de novo and inherited mutations of the CASR gene and assist in management decisions.
[more...]
|
Evolution of Secondary Hyperparathyroidism After Kidney Transplantation in Patients Receiving Cinacalcet on Dialysis
Transplantation Proceedings, 09/11/2009
|
JV et al. – In patients with HPT undergoing dialysis and receiving cinacalcet, 60 mg/d or more, this drug therapy should be continued after KTx to avert development of hypercalcemia or hypophosphatemia.
[more...]
|
Treatment With Cinacalcet in 29 Kidney Transplant Patients With Persistent Hyperparathyroidism
Transplantation Proceedings, 09/16/2009
|
Lopez V et al. – Cinacalcet was safe and effective in kidney transplant patients with hypercalcemia secondary to HPT. Of note was the low incidence of adverse side effects despite the high doses prescribed for these patients.
[more...]
|
Treatment of Persistent Hyperparathyroidism in Renal Transplant Patients With Cinacalcet Improves Control of Blood Pressure
Transplantation Proceedings, 09/03/2009
|
another one because the iPTH was reduced to 51 pg/mL. Cinacalcet is an effective treatment for persistent hyperparathyroidism associated with hypercalcemia among renal transplant patients and may be helpful for hypertension control.
[more...]
|
Treatment With Cinacalcet of Secondary Hyperparathyroidism After Renal Transplantation
Transplantation Proceedings, 09/17/2009
|
Marques GG et al. – Treatment with cinacalcet controlled hyperparathyroidism and hypercalcemia among patients with posttransplant SHP. It was a safe drug, with a low incidence of side effects.
[more...]
|
Supportive therapy of urogenital tumors
Der Urologe, 10/13/2009
|
gives a brief synopsis of the current literature on the diagnosis and therapy concerning anemia thrombotic events and tumor–related hypercalcemia as well as recommendations on treating therapy–associated neutropenia.
[more...]
|
Hypothesis: Sarcoidosis is a STAT1-mediated disease
Clinical Immunology, 08/05/2009
|
with regard to sarcoidosis including implication of a casual role for interferons, a suspected infectious trigger, TH1 predominating lymphocytes in bronchoalveolar lavage, and the association with hypercalcemia.
[more...]
|
